KR20040048404A - 혈관형성 억제 활성을 가지며 응고억제 효과는 없는,헤파라나제 억제제로서 부분적으로 탈황산화된글리코스아미노글리칸의 유도체 - Google Patents
혈관형성 억제 활성을 가지며 응고억제 효과는 없는,헤파라나제 억제제로서 부분적으로 탈황산화된글리코스아미노글리칸의 유도체 Download PDFInfo
- Publication number
- KR20040048404A KR20040048404A KR10-2004-7003203A KR20047003203A KR20040048404A KR 20040048404 A KR20040048404 A KR 20040048404A KR 20047003203 A KR20047003203 A KR 20047003203A KR 20040048404 A KR20040048404 A KR 20040048404A
- Authority
- KR
- South Korea
- Prior art keywords
- heparin
- acid
- acetyl
- partially
- uronic acid
- Prior art date
Links
- 108010037536 heparanase Proteins 0.000 title claims abstract description 49
- 102100024025 Heparanase Human genes 0.000 title claims abstract description 47
- 229920002683 Glycosaminoglycan Polymers 0.000 title claims abstract description 20
- 239000003112 inhibitor Substances 0.000 title description 16
- 230000002429 anti-coagulating effect Effects 0.000 title description 4
- 230000001772 anti-angiogenic effect Effects 0.000 title description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 135
- 229960002897 heparin Drugs 0.000 claims abstract description 126
- 229920000669 heparin Polymers 0.000 claims abstract description 120
- 150000001875 compounds Chemical class 0.000 claims abstract description 85
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 52
- 230000033115 angiogenesis Effects 0.000 claims abstract description 28
- 239000002253 acid Substances 0.000 claims description 88
- 238000006477 desulfuration reaction Methods 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 36
- 230000023556 desulfurization Effects 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 24
- 125000003047 N-acetyl group Chemical group 0.000 claims description 22
- 150000004676 glycans Polymers 0.000 claims description 21
- 206010027476 Metastases Diseases 0.000 claims description 18
- 125000003700 epoxy group Chemical group 0.000 claims description 17
- 230000009401 metastasis Effects 0.000 claims description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 15
- 150000004804 polysaccharides Polymers 0.000 claims description 15
- 150000002482 oligosaccharides Chemical class 0.000 claims description 14
- 229920001542 oligosaccharide Polymers 0.000 claims description 13
- 230000002829 reductive effect Effects 0.000 claims description 13
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 239000003102 growth factor Substances 0.000 claims description 12
- 230000036961 partial effect Effects 0.000 claims description 12
- 125000003172 aldehyde group Chemical group 0.000 claims description 11
- 150000001720 carbohydrates Chemical class 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- LCTORNIWLGOBPB-GASJEMHNSA-N (3r,4s,5s,6r)-2-amino-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical group NC1(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LCTORNIWLGOBPB-GASJEMHNSA-N 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 9
- 150000007524 organic acids Chemical class 0.000 claims description 9
- 230000003647 oxidation Effects 0.000 claims description 9
- 238000007254 oxidation reaction Methods 0.000 claims description 9
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 9
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 125000002252 acyl group Chemical group 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 claims description 5
- 230000009615 deamination Effects 0.000 claims description 5
- 238000006481 deamination reaction Methods 0.000 claims description 5
- 150000002338 glycosides Chemical group 0.000 claims description 5
- 108010022901 Heparin Lyase Proteins 0.000 claims description 4
- 230000006181 N-acylation Effects 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000003511 endothelial effect Effects 0.000 claims description 4
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 4
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 4
- 150000002337 glycosamines Chemical group 0.000 claims description 4
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 206010018366 Glomerulonephritis acute Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 108090000856 Lyases Proteins 0.000 claims description 2
- 102000004317 Lyases Human genes 0.000 claims description 2
- 101710170181 Metalloproteinase inhibitor Proteins 0.000 claims description 2
- 208000013544 Platelet disease Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010038934 Retinopathy proliferative Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- KZWHEHSUEBTKJM-SLPGGIOYSA-N [(2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-1-oxohexan-2-yl]sulfamic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NS(O)(=O)=O KZWHEHSUEBTKJM-SLPGGIOYSA-N 0.000 claims description 2
- 231100000851 acute glomerulonephritis Toxicity 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 238000004220 aggregation Methods 0.000 claims description 2
- 238000002399 angioplasty Methods 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 210000004351 coronary vessel Anatomy 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 150000002009 diols Chemical class 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 230000003176 fibrotic effect Effects 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 229940126170 metalloproteinase inhibitor Drugs 0.000 claims description 2
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 150000003138 primary alcohols Chemical class 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 210000002460 smooth muscle Anatomy 0.000 claims description 2
- 230000003637 steroidlike Effects 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- IAJILQKETJEXLJ-LECHCGJUSA-N iduronic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-LECHCGJUSA-N 0.000 claims 4
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 239000002257 antimetastatic agent Substances 0.000 claims 1
- 208000027744 congestion Diseases 0.000 claims 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 230000015271 coagulation Effects 0.000 abstract description 8
- 238000005345 coagulation Methods 0.000 abstract description 8
- 229920002971 Heparan sulfate Polymers 0.000 description 36
- 239000000243 solution Substances 0.000 description 26
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 22
- 230000000694 effects Effects 0.000 description 18
- 230000005764 inhibitory process Effects 0.000 description 17
- 101150021185 FGF gene Proteins 0.000 description 16
- AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical compound OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 8
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 210000002744 extracellular matrix Anatomy 0.000 description 8
- 239000002628 heparin derivative Substances 0.000 description 8
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 8
- 238000007142 ring opening reaction Methods 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000006640 acetylation reaction Methods 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- -1 acyl anhydride Chemical class 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 108091008794 FGF receptors Proteins 0.000 description 4
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 4
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 108090000054 Syndecan-2 Proteins 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical group O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 3
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000004019 antithrombin Substances 0.000 description 3
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 150000002118 epoxides Chemical class 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 230000005747 tumor angiogenesis Effects 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
- 108010060309 Glucuronidase Proteins 0.000 description 2
- 102000053187 Glucuronidase Human genes 0.000 description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
- 241000872931 Myoporum sandwicense Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 239000000701 coagulant Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 239000002634 heparin fragment Substances 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000003055 low molecular weight heparin Substances 0.000 description 2
- 229940127215 low-molecular weight heparin Drugs 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 125000001483 monosaccharide substituent group Chemical group 0.000 description 2
- INLBBXWDZGULCP-XJSRCERCSA-A octadecasodium;[(2r,3r,4s,5s,6r)-6-[(2r,3s,4s,5r,6r)-2-[(2r,3s,4s,5r,6r)-2-[(2r,3r,4s,5s,6r)-3,5-disulfonatooxy-2-(sulfonatooxymethyl)-6-[(2r,3s,4r,5r,6r)-2,4,5-trisulfonatooxy-6-(sulfonatooxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-3,5-disulfonatooxy-6-(sulfona Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)O[C@H]1[C@@H](OS([O-])(=O)=O)[C@H](OS([O-])(=O)=O)[C@@H](COP([O-])(=O)[O-])O[C@@H]1O[C@@H]1[C@H](OS([O-])(=O)=O)[C@@H](O[C@@H]2[C@@H]([C@@H](O[C@@H]3[C@@H]([C@@H](O[C@H]4[C@H]([C@H](OS([O-])(=O)=O)[C@@H](COS([O-])(=O)=O)O[C@@H]4OS([O-])(=O)=O)OS([O-])(=O)=O)O[C@H](COS([O-])(=O)=O)[C@H]3OS([O-])(=O)=O)OS([O-])(=O)=O)O[C@H](COS([O-])(=O)=O)[C@H]2OS([O-])(=O)=O)OS([O-])(=O)=O)O[C@H](COS([O-])(=O)=O)[C@H]1OS([O-])(=O)=O INLBBXWDZGULCP-XJSRCERCSA-A 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 125000000466 oxiranyl group Chemical group 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003222 pyridines Chemical class 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- IAJILQKETJEXLJ-MGCNEYSASA-N (2r,3s,4r,5s)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid Chemical group O=C[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C(O)=O IAJILQKETJEXLJ-MGCNEYSASA-N 0.000 description 1
- IAJILQKETJEXLJ-KLVWXMOXSA-N (2s,3r,4r,5r)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid Chemical compound O=C[C@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-KLVWXMOXSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 description 1
- OCIBBXPLUVYKCH-QXVNYKTNSA-N alpha-maltohexaose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](O[C@H](O[C@@H]3[C@H](O[C@H](O[C@@H]4[C@H](O[C@H](O[C@@H]5[C@H](O[C@H](O)[C@H](O)[C@H]5O)CO)[C@H](O)[C@H]4O)CO)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O OCIBBXPLUVYKCH-QXVNYKTNSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940037157 anticorticosteroids Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 125000001721 carboxyacetyl group Chemical group 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000002477 conductometry Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000000447 dimerizing effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MEPLNBPJJKOWLV-UHFFFAOYSA-N hexanedioic acid;hydrazine Chemical compound NN.OC(=O)CCCCC(O)=O MEPLNBPJJKOWLV-UHFFFAOYSA-N 0.000 description 1
- 125000005597 hydrazone group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- AEMOLEFTQBMNLQ-CLQWQSTFSA-N l-iduronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O AEMOLEFTQBMNLQ-CLQWQSTFSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- DJMVHSOAUQHPSN-UHFFFAOYSA-N malto-hexaose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(OC4C(C(O)C(O)C(CO)O4)O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 DJMVHSOAUQHPSN-UHFFFAOYSA-N 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 125000003431 oxalo group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000017363 positive regulation of growth Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010613 succinylation reaction Methods 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000005987 sulfurization reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
- C08B37/0078—Degradation products
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
Description
25 ㎍/㎖ 내지 5 ㎍/㎖ 범위의 용량에서 헤파라나제 억제 | ||||
억제 | ||||
용량 | 25 ㎍/㎖ | 10 ㎍/㎖ | 5 ㎍/㎖ | |
헤파린 | 100% | n.d. | >100% | |
ST1516 | 헤파린 40% RO | 100% | n.d. | >85% |
ST1514 | 헤파린 ∼50% RO | 100% | 100% | >85% |
ST1515 | 헤파린 27.5% RO | 100% | 100% | 100% |
ST1518 | 50% NAc 헤파린 30% RO | 100% | 100% | >85% |
Claims (24)
- 헤파라나제 억제 활성 및/또는 FGF 성장 인자 억제 활성을 갖는 약물의 제조를 위한, 탈황산화 정도가 전체 유론산 단위의 60% 이하인 글리코스아미노글리칸 유도체, 특히 탈황산화된 헤파린의 용도.
- 제 1 항에 있어서, 유도체가 헤파린 유사 글리코스아미노글리칸인 용도.
- 제 1 항 또는 제 2 항에 있어서, 유도체가 상이한 정도의 N-탈황산화 및 임의적인 후속의 전체 또는 부분 N-아실화를 갖는 글리코스아민 잔기를 함유하는 변경된 헤파린인 용도.
- 제 1 항 또는 제 3 항에 있어서, 유도체가 하기 화학식 I을 갖는 용도:화학식 I상기 식에서,U 고리는 하기의 의미를 가질 수 있고:X 및 X'는 동일하거나 상이하게, 알데히드 그룹 또는 -CH2-D 그룹이고, 이때 D는 하이드록시 또는 아미노산, 펩티드, 또는 탄수화물 또는 올리고사카라이드의 잔기이며;R 및 R1은 동일하거나 상이하게, SO3, 임의로 적어도 추가의 카복시 그룹을 갖는C1-C8아실 잔기이고;n 및 m은 동일하거나 상이하게, 1 내지 40으로 다양할 수 있으며; n+m의 합은 6 내지 40의 범위이고; m:n 비는 10:2 내지 1:1의 범위이며;기호는 표시된 m 및 n 단위들이 폴리사카라이드 쇄를 따라 통계학적으로 분포되고 반드시 차례대로 있지는 않음을 가리킨다.
- 제 4 항에 있어서, R 또는 R1이 N-아실 그룹이고 R+R1합의 40 내지 60%의 범위인 용도.
- 제 4 항 또는 제 5 항에 있어서, R 및 R1이 동일하거나 상이하게 아세틸인 용도.
- 제 4 항 내지 제 6 항 중 어느 하나의 항에 있어서, m이 n 이상인 용도.
- 제 5 항 또는 제 6 항에 있어서, n의 범위가 m+n 합의 40 내지 60%인 용도.
- 제 4 항에 있어서, 유도체가 하기로 이루어진 그룹 중에서 선택되는 용도:-분자량(MW) 11200, 다분산 지수 D 1.3, 탈황산화 정도 1.99(SO3 -:COO-몰비로서 나타냄)를 가지며 전체 유론산에 대해 변경된 유론산의 퍼센트가 약 50%이고, m:n=1:1이며 m 및 n 표시된 단위가 규칙적인 교번 방식으로 폴리사카라이드 쇄를 따라 분포되는 부분적으로 2-O-탈황산화된 헤파린;-분자량(MW) 3050, 다분산 지수 2.2, 탈황산화 정도 1.99(SO3 -:COO-몰비로서 나타냄)를 가지며 전체 유론산에 대해 변경된 유론산의 퍼센트가 약 50%이고, m:n=1:1이며 m 및 n 표시된 단위가 규칙적인 교번 방식으로 폴리사카라이드 쇄를 따라 분포되는 부분적으로 2-O-탈황산화된 LMW 헤파린;-Mn=5800, Mw=7520의 분자량, 다분산 지수 1.294를 가지며 전체 유론산에 대해 변경된 유론산의 퍼센트가 약 50%이고, m:n=1:1이며 m 및 n 표시된 단위가 규칙적인 교번 방식으로 폴리사카라이드 쇄를 따라 분포되는 부분적으로 2-O-탈황산화된 LMW 헤파린;-분자량(MW) 12900 D, 다분산 지수 D 1.5, 탈황산화 정도 1.9(SO3 -:COO-몰비로서 나타냄)를 가지며 전체 유론산에 대해 변경된 유론산의 퍼센트가: 에폭사이드 그룹5%, 산화 및 환원된 유론산 잔기 29%이고, m:n=1:1이며 m 및 n 표시된 단위가 규칙적인 교번 방식으로 폴리사카라이드 쇄를 따라 분포되는 부분적으로 2-O-탈황산화된 헤파린;-분자량(MW) 9200 D, 다분산 지수 D 1.5를 가지며 전체 유론산에 대해 변경된 유론산의 퍼센트가: 에폭사이드 그룹 11%, 산화 및 환원된 유론산 잔기 27.5%이고, m:n=1:1이며 m 및 n 표시된 단위가 규칙적인 교번 방식으로 폴리사카라이드 쇄를 따라 분포되는 부분적으로 2-O-탈황산화된 헤파린;-분자량(MW) 11000 D, 다분산 지수 D 1.5, 탈황산화 정도 1.93(SO3 -:COO-몰비로서 나타냄)을 가지며 전체 유론산에 대해 변경된 유론산의 퍼센트가: 에폭사이드 그룹 5%, 산화 및 환원된 유론산 잔기 29%인 2-O-탈황산화된 헤파린.
- 제 4 항에 있어서, 유도체가 하기로 이루어진 그룹 중에서 선택되는 용도:-분자량(MW) 11250, 다분산 지수 1.66, 탈황산화 정도 1.7(SO3 -:COO-몰비로서 나타냄)을 가지며 전체 유론산에 대해 변경된 유론산의 퍼센트가 약 30%이고, R 및 R1합의 50%가 N-아세틸인 부분적으로 N-탈황산화되고 N-재아세틸화된 헤파린;-Mn=4780, Mw=10000의 분자량, 다분산 지수 D 2.092를 가지며 전체 유론산에 대해 변경된 유론산의 퍼센트가 약 30%이고, R 및 R1합의 50%가 N-아세틸인 부분적으로N-탈황산화되고 N-재아세틸화된 LMW 헤파린;-Mn=10890, Mw=22370의 분자량, 다분산 지수 2.054를 가지며, R 및 R1합의 27%가 N-아세틸인 부분적으로 N-탈황산화되고 N-재아세틸화된 헤파린;-Mn=10210, Mw=21270의 분자량, 다분산 지수 2.083을 가지며, R 및 R1합의 39%가 N-아세틸인 부분적으로 N-탈황산화되고 N-재아세틸화된 헤파린;-Mn=11070, Mw=22000의 분자량, 다분산 지수 1.987을 가지며, R 및 R1합의 64%가 N-아세틸인 부분적으로 N-탈황산화되고 N-재아세틸화된 헤파린;-전체 유론산에 대해 변경된 유론산의 퍼센트가 약 30%이고, R 및 R1합의 27%가 N-아세틸인 부분적으로 N-탈황산화되고 N-재아세틸화된 헤파린;-전체 유론산에 대해 변경된 유론산의 퍼센트가 약 30%이고, R 및 R1합의 39%가 N-아세틸인 부분적으로 N-탈황산화되고 N-재아세틸화된 헤파린;-전체 유론산에 대해 변경된 유론산의 퍼센트가 약 30%이고, R 및 R1합의 64%가 N-아세틸인 부분적으로 N-탈황산화되고 N-재아세틸화된 헤파린.
- 제 1 항 내지 제 10 항 중 어느 하나의 항에 있어서, 약물이 혈관형성 억제 활성을 갖는 용도.
- 제 1 항 내지 제 10 항 중 어느 하나의 항에 있어서, 약물이 염증의 치료에 유용한 용도.
- 제 1 항 내지 제 10 항 중 어느 하나의 항에 있어서, 약물이 자가면역 질환의 치료에 유용한 용도.
- 제 1 항 내지 제 10 항 중 어느 하나의 항에 있어서, 치료되는 질환이 1 차 종양, 전이, 당뇨성 망막병증, 건선, 수정체뒤 섬유증식, 혈관성형술 뒤 재 협착증, 심장동맥 바이패스, 염증, 관절염, 자가면역 질환, 동종이식 거부, 심혈관 질환, 섬유증식성 질환, 비정상적인 혈소판 응집에 의해 유도된 질환, 평활근 증식에 의해 유도된 질환, 굳패스추어 증후군, 급성 사구체신염, 신생아 폐 고혈압, 천식, 울혈성 심부전, 성인 폐 고혈압, 신장 혈관 고혈압, 증식성 망막병증, 실험적인 자가면역 뇌척수염, 다발성 경화증, 인슐린 의존성 당뇨병, 염증성 장 질환, 궤양성 대장염, 크론병으로 이루어진 그룹 중에서 선택되는 용도.
- 하기 화학식 I의 화합물:화학식 I상기 식에서,U 고리는 하기의 의미를 가질 수 있고:X 및 X'는 동일하거나 상이하게, 알데히드 그룹 또는 -CH2-D 그룹이고, 이때 D는 하이드록시 또는 아미노산, 펩티드, 또는 탄수화물 또는 올리고사카라이드의 잔기이며;R 및 R1은 동일하거나 상이하게, SO3, C1또는 C3-C8아실 잔기이고;n 및 m은 동일하거나 상이하게, 1 내지 40으로 다양할 수 있으며; n+m의 합은 6 내지 40의 범위이고; m:n 비는 10:2 내지 1:1의 범위이며;기호는 표시된 m 및 n 단위들이 폴리사카라이드 쇄를 따라 통계학적으로 분포되고 반드시 차례대로 있지는 않음을 가리킨다.
- 제 15 항에 있어서, -분자량(MW) 11250, 다분산 지수 1.66, 탈황산화 정도 1.7(SO3 -:COO-몰비로서 나타냄)을 가지며 전체 유론산에 대해 변경된 유론산의 퍼센트가 약 30%이고, R 및 R1합의 50%가 N-아세틸인 부분적으로 N-탈황산화되고 N-재아세틸화된 헤파린;-Mn=4780, Mw=10000의 분자량, 다분산 지수 2.092를 가지며 전체 유론산에 대해 변경된 유론산의 퍼센트가 약 30%이고, R 및 R1합의 50%가 N-아세틸인 부분적으로 N-탈황산화되고 N-재아세틸화된 LMW 헤파린;-Mn=10890, Mw=22370의 분자량, 다분산 지수 2.054를 가지며, R 및 R1합의 27%가 N-아세틸인 부분적으로 N-탈황산화되고 N-재아세틸화된 헤파린;-Mn=10210, Mw=21270의 분자량, 다분산 지수 2.083을 가지며, R 및 R1합의 39%가 N-아세틸인 부분적으로 N-탈황산화되고 N-재아세틸화된 헤파린;-Mn=11070, Mw=22000의 분자량, 다분산 지수 1.987을 가지며, R 및 R1합의 64%가N-아세틸인 부분적으로 N-탈황산화되고 N-재아세틸화된 헤파린;-전체 유론산에 대해 변경된 유론산의 퍼센트가 약 30%이고, R 및 R1합의 27%가 N-아세틸인 부분적으로 N-탈황산화되고 N-재아세틸화된 헤파린으로 이루어진 그룹 중에서 선택되는 화합물.
- a) 주변 온도에서 0.5 내지 8 시간 범위의 시간 동안 DMSO:H2O 95:5(v/v) 중에서 설프아미노 잔기를 가용매분해적 가수분해에 의해 N-탈황산화시켜 글루코스아민 잔기의 2 번 위치에서 설페이트 그룹을 전적으로 또는 부분적으로 제거하는 단계;b) 아실화제와 함께 알칼리성 수용액(pH 8-9)으로 처리하여 상기 글루코스아민 잔기의 2 번 위치에서 전적으로 또는 부분적으로 탈황산화된 그룹을 N-아실화시켜 상기 글루코스아민 잔기의 2 번 위치에 전적으로 또는 부분적으로 아실화된 그룹을 제공하고; 이어서 수득된 화합물을 하기 단계 c), d) 또는 e) 및 f 내지 g)에 제공하거나, 또는 달리 하기 단계 f)에 직접 제공하는 단계;c) 주변 온도 내지 약 100 ℃ 범위의 온도에서 염기성 처리에 의해 이두론산의 2 번 위치에서 조절된 퍼센트의 설페이트 그룹을 제거하고 에폭사이드 그룹을 형성시키는 단계; 및 경우에 따라d) 약 pH 7, 약 50 내지 약 100 ℃ 범위의 온도에서 상기 에폭사이드 고리를개환시켜 갈락투론산의 잔기를 수득하는 단계; 또는 한편으로e) 약 0 내지 30 ℃ 범위의 온도에서 상기 에폭사이드 고리를 개환시켜 이두론산의 잔기를 수득하는 단계; 및 경우에 따라f) 디올을 나트륨 페리오데이트에 의해 산화시켜 글리코사이드 고리를 개환시키고 변경된 잔기 당 2 개의 알데히드 그룹을 형성시키는 단계;g) 상기 알데히드 그룹을 1 차 알콜로 환원시키고, 경우에 따라 D 그룹을 하이드록실 이외의 그룹(화학식 I에 나타낸 상이한 의미들에서 고려된 바와 같음)으로 전환시키는 단계;h) 단계 g)에서 수득된 화합물을 임의적으로 산 가수분해시켜 규칙적인 서열에 상응하는 올리고사카라이드를 수득하는 단계; 또는 한편으로i) 단계 g)에서 수득된 생성물을 리아제, 헤파리나제, 헤파리티나제 및 이의 등가물로 이루어진 그룹 중에서 선택된 효소를 사용하는 부분적인 효소 가수분해에 제공하여, 불포화 이두론산으로 이루어진 비 환원 말단 잔기, N-설포글루코스아민으로 이루어지고 개방 이두론산의 하나 이상의 잔기를 함유하는 환원 잔기를 갖는 올리고사카라이드, 바람직하게는 테트라- 또는 옥타-사카라이드를 수득하는 단계;j) 임의로 단계 c)에서 수득된 화합물 또는 단계 d)에서 수득된 생성물을 부분적인 효소 가수분해에 의해 처리하는 단계; 및 경우에 따라k) 단계 b), c) 및 f) 중 하나에서 수득된 생성물에 부분적인 6-O 탈황산화를 가하는 단계; 또는 한편으로l) 부분적으로 또는 전적으로 6-탈황산화된 출발 헤파린에 단계 b), c) 및f)를 가하는 단계;를 포함하는 제 15 항 또는 제 16 항에 따른 화합물의 제조 방법.
- 제 17 항의 방법에 의해 수득할 수 있는 화합물.
- -단계 a)를 실온에서 2 시간 동안 수행하고 단계 b)를 4 ℃에서 2 시간 동안 수행하며 단계 c), d), e)를 생략하고 단계 f)를 4 ℃에서 밤새 수행하며 단계 g)를 실온에서 3 시간 동안 수행하여 수득할 수 있고, 분자량(MW) 11200, 다분산 지수 D 1.3, 탈황산화 정도 1.6(SO3 -:COO-몰비로서 나타냄)을 가지며 전체 유론산에 대해 변경된 유론산의 퍼센트가 약 50%인 헤파린 N-아세틸(50%);-단계 a)를 실온에서 2 시간 동안 수행하고 단계 b)를 4 ℃에서 2 시간 동안 수행하며, 단계 c), d), e)를 생략하고 단계 f)를 4 ℃에서 밤새 수행하며, 단계 g)를 실온에서 3 시간 동안 수행하고, 단계 h)를 4 ℃에서 17 분간 아질산 탈아민화에 이어서 실온에서 3 시간 동안 붕수소화물에 의한 알데히드 그룹의 환원에 의해 수행하여 수득할 수 있고, Mn=4780, Mw=10000의 분자량, 다분산 지수 D 2.092를 가지며 전체 유론산에 대해 변경된 유론산의 퍼센트가 약 30%인 LMW 헤파린 N-아세틸(50%);-단계 a)를 실온에서 2 시간 동안 수행하고, 단계 b)를 4 ℃에서 2 시간 동안 수행하며, 단계 c), d), e), f), g), h)를 생략하여 수득할 수 있고, Mn=10890, Mw=22370의 분자량, 다분산 지수 D 2.054를 갖는 헤파린 N-아세틸(27%);-단계 a)를 실온에서 2 시간 동안 수행하고, 단계 b)를 4 ℃에서 2 시간 동안 수행하며, 단계 c), d), e), f), g), h)를 생략하여 수득할 수 있고, Mn=10210, Mw=21270의 분자량, 다분산 지수 D 2.083을 갖는 헤파린 N-아세틸(39%);-단계 a)를 실온에서 2 시간 동안 수행하고, 단계 b)를 4 ℃에서 2 시간 동안 수행하며, 단계 c), d), e), f), g), h)를 생략하여 수득할 수 있고, Mn=11070, Mw=22000의 분자량, 다분산 지수 D 1.987을 갖는 헤파린 N-아세틸(64%);-단계 a)를 실온에서 2 시간 동안 수행하고, 단계 b)를 4 ℃에서 2 시간 동안 수행하며, 단계 c), d), e), f), g), h)를 생략하여 수득할 수 있고, 전체 유론산에 대해 변경된 유론산의 퍼센트가 약 30%인 헤파린 N-아세틸(27%);-단계 a)를 실온에서 2 시간 동안 수행하고, 단계 b)를 4 ℃에서 2 시간 동안 수행하며, 단계 c), d), e), f), g), h)를 생략하여 수득할 수 있고, 전체 유론산에 대해 변경된 유론산의 퍼센트가 약 30%인 헤파린 N-아세틸(39%);-단계 a)를 실온에서 2 시간 동안 수행하고, 단계 b)를 4 ℃에서 2 시간 동안 수행하며, 단계 c), d), e), f), g), h)를 생략하여 수행한 상술한 방법에 의해 수득할 수 있고, 전체 유론산에 대해 변경된 유론산의 퍼센트가 약 30%인 헤파린 N-아세틸(64%)로 이루어진 그룹 중에서 선택되는 제 17 항의 방법에 의해 수득할 수 있는 화합물.
- 유효 성분으로서 적어도 하나 이상의 제 15 항, 제 16 항 및 제 19 항 중 어느 하나의 항의 화합물을 약학적으로 허용 가능한 비히클 및 부형제와의 혼합물로 함유하는 약학 조성물.
- 약물로서 제 15 항, 제 16 항 및 제 19 항 중 어느 하나의 항의 화합물의 용도.
- 약물에 대한 비히클로서 제 15 항, 제 16 항 및 제 19 항 중 어느 하나의 항의 화합물의 용도.
- 제 22 항에 있어서, 약물이 스테로이드성 및 비 스테로이드성 소염 약물, 코르티코스테로이드, 전이억제 작용을 갖는 약물, 내피 수준에서 작용하는 약물로 이루어진 그룹 중에서 선택되는 용도.
- 제 23 항에 있어서, 전이억제 약물이 메탈로프로테이나제 억제제인 용도.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IT2001/000472 WO2003022291A1 (en) | 2001-09-12 | 2001-09-12 | Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040048404A true KR20040048404A (ko) | 2004-06-09 |
KR100855331B1 KR100855331B1 (ko) | 2008-09-04 |
Family
ID=11133723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047003203A KR100855331B1 (ko) | 2001-09-12 | 2001-09-12 | 혈관형성 억제 활성을 가지며 응고억제 효과는 없는,헤파라나제 억제제로서 부분적으로 탈황산화된글리코스아미노글리칸의 유도체 |
Country Status (20)
Country | Link |
---|---|
US (1) | US20050137167A1 (ko) |
EP (2) | EP2343077B1 (ko) |
JP (1) | JP2005506326A (ko) |
KR (1) | KR100855331B1 (ko) |
CN (1) | CN1547477B (ko) |
AT (1) | ATE511846T1 (ko) |
AU (1) | AU2001292231B2 (ko) |
BR (1) | BR0117124A (ko) |
CA (1) | CA2457719C (ko) |
CY (2) | CY1112551T1 (ko) |
CZ (1) | CZ307433B6 (ko) |
DK (1) | DK1427427T3 (ko) |
ES (2) | ES2367778T3 (ko) |
HK (1) | HK1069537A1 (ko) |
HU (1) | HU230385B1 (ko) |
MX (1) | MXPA04002217A (ko) |
PT (2) | PT2343077E (ko) |
SI (1) | SI1427427T1 (ko) |
SK (1) | SK288335B6 (ko) |
WO (1) | WO2003022291A1 (ko) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060293275A1 (en) * | 2004-03-29 | 2006-12-28 | Toshikazu Nakamura | Hgf production accelerator containing heparin-like oligosaccharide |
CA2666840C (en) * | 2006-10-20 | 2015-07-14 | The Australian National University | Inhibition of degradation of extracellular matrix |
WO2009007224A1 (en) * | 2007-07-10 | 2009-01-15 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Low molecular weight heparin derivatives having neuroprotective activity |
US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
US8592393B2 (en) | 2007-11-02 | 2013-11-26 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
EP2205642B1 (en) | 2007-11-02 | 2016-01-27 | Momenta Pharmaceuticals, Inc. | Non-anticoagulant polysaccharide compositions |
FI20085308A0 (fi) * | 2008-04-11 | 2008-04-11 | Polysackaridforskning I Uppsal | Heparanaasittomia ihmiskuntaan kuulumattomia nisäkkäitä |
FR2949115B1 (fr) * | 2009-08-14 | 2012-11-02 | Sanofi Aventis | OLIGOSACCHARIDES N-SULFATES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
CN102917711A (zh) * | 2010-03-12 | 2013-02-06 | 澳大利亚国立大学 | 硫酸乙酰肝素替代疗法 |
CN102985443B (zh) | 2010-04-16 | 2017-05-10 | 动量制药公司 | 组织靶向 |
AU2011268470B2 (en) | 2010-06-17 | 2017-02-02 | Momenta Pharmaceuticals, Inc. | Methods and compositions for promoting hair growth |
FR2970969B1 (fr) * | 2011-01-27 | 2013-10-18 | Sanofi Aventis | Oligosaccharides 3-o-alkyles activateurs des recepteurs des fgfs, leur preparation et leur application en therapeutique |
KR101522604B1 (ko) * | 2013-03-21 | 2015-05-26 | 대한민국 | 곤충 글라이코자미노글라이칸 유래 헤파린 단편 및 이의 제조 방법 |
RU2700877C2 (ru) * | 2013-05-16 | 2019-09-23 | Эдженси Фо Сайенс, Текнолоджи Энд Ресёрч | Гепарансульфаты |
US10016449B2 (en) | 2013-05-28 | 2018-07-10 | Momenta Pharmaceuticals, Inc. | Pharmaceutical compositions |
ITLO20130005A1 (it) * | 2013-10-31 | 2015-05-01 | He E Biochimiche G Ronzonr S R | Derivati di glucosamminoglicani n-desolfatati e loro uso come farmaci |
ITLO20130006A1 (it) | 2013-11-06 | 2015-05-07 | He E Biochimiche G Ronzoni S R | Derivati carbossilati di glucosamminoglicani e loro uso come farmaci |
US10576101B2 (en) | 2015-03-06 | 2020-03-03 | Leadiant Biosciences Sa | Roneparstat combined therapy of multiple myeloma |
AU2017376817B2 (en) | 2016-12-13 | 2022-03-31 | Beta Therapeutics Pty Ltd | Heparanase inhibitors and use thereof |
US11787783B2 (en) | 2016-12-13 | 2023-10-17 | Beta Therapeutics Pty Ltd | Heparanase inhibitors and use thereof |
CN108424474B (zh) * | 2017-02-15 | 2023-07-25 | 清华大学 | 去抗凝肝素衍生物及其用于炎症性肠病的治疗 |
EP3601312A4 (en) * | 2017-03-23 | 2020-12-23 | Victoria Link Limited | GLYCOMIMETIC COMPOUNDS OF HEPARAN SULPHATE AND THEIR PHARMACEUTICAL AND COSMETIC USES |
EP3388439A1 (en) | 2017-04-11 | 2018-10-17 | Leadiant Biosciences SA | Biotin-conjugated n-acetyl glycol split heparin |
WO2019149179A1 (zh) * | 2018-02-02 | 2019-08-08 | 深圳市海普瑞药业集团股份有限公司 | 糖胺聚糖衍生物及其制备方法和用途 |
EP3705126A1 (en) | 2019-03-05 | 2020-09-09 | Leadiant Biosciences S.p.A. | Roneparstat for the treatment of amyloidosis |
CN114901702B (zh) * | 2019-12-27 | 2024-01-09 | 深圳市海普瑞药业集团股份有限公司 | 一种糖胺聚糖衍生物及其应用 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5262403A (en) * | 1986-03-10 | 1993-11-16 | Board Of Regents, The University Of Texas System | Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II |
JPS62265998A (ja) * | 1986-03-10 | 1987-11-18 | ボ−ド オブ リ−ジエンツ ザ ユニヴア−シテイ オブ テキサス システム | ヘパラン硫酸エンドグリコシダーゼアッセイ |
IE61758B1 (en) | 1986-05-23 | 1994-11-30 | Daiichi Seiyaku Co | Use of a sulfated polysaccharide |
IL79254A0 (en) | 1986-06-26 | 1986-09-30 | Hadassah Med Org | Compositions for preventing graft rejection |
IL79255A0 (en) * | 1986-06-26 | 1986-09-30 | Hadassah Med Org | Composition for metastasis prevention |
AU7852687A (en) * | 1986-08-21 | 1988-03-08 | University Of Texas System, The | Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness or metastatic profusion |
IL85145A (en) | 1987-01-23 | 1994-08-26 | Univ Australian | Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity |
FR2614026B1 (fr) * | 1987-04-16 | 1992-04-17 | Sanofi Sa | Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques |
PT93847A (pt) | 1989-04-24 | 1990-11-20 | Harvard College | Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem |
US5474765A (en) | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
CZ195193A3 (en) | 1992-09-25 | 1994-04-13 | Lilly Co Eli | Modified factor-4 of blood platelets, process of its preparation and pharmaceutical preparation in which it is comprised |
US5296471A (en) * | 1992-12-22 | 1994-03-22 | Glycomed Incorporated | Method for controlling o-desulfation of heparin and compositions produced thereby |
US5696100A (en) * | 1992-12-22 | 1997-12-09 | Glycomed Incorporated | Method for controlling O-desulfation of heparin and compositions produced thereby |
US5399667A (en) | 1993-03-05 | 1995-03-21 | Washington University | Thrombospondin receptor binding peptides |
IT1264101B1 (it) | 1993-03-29 | 1996-09-10 | Alfa Wassermann Spa | Processo per la sintesi di glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2 |
IT1264709B1 (it) * | 1993-07-12 | 1996-10-04 | Italfarmaco Spa | Derivati eparinici ad attivita' antimetastatica |
AU7520394A (en) | 1993-08-13 | 1995-03-14 | Glycomed Incorporated | Bridged oligosaccharides and sulfated derivatives thereof |
US5739115A (en) | 1993-10-07 | 1998-04-14 | Glycomed Incorporated | Sulfated maltooligosaccharides with heparin-like properties |
AU700451B2 (en) | 1993-10-07 | 1999-01-07 | Glycomed Incorporated | Highly sulfated maltooligosaccharides with heparin-like properties |
CA2189038A1 (en) | 1994-05-06 | 1995-11-09 | Kevin R. Holme | O-desulfated heparin derivatives, methods of making and uses thereof |
AUPN261895A0 (en) | 1995-04-28 | 1995-05-18 | Australian National University, The | Preparation and use of sulfated oligosaccharides |
JP4051099B2 (ja) * | 1997-01-31 | 2008-02-20 | 生化学工業株式会社 | 低分子化ヘパリン、その製造法及び医薬組成物 |
DE19955803A1 (de) | 1999-11-19 | 2001-05-23 | Knoll Ag | Verwendung von Heparanase-Inhibitoren zur Behandlung von Hersinsuffizienz |
AU3078800A (en) * | 2000-01-25 | 2001-08-07 | Nippon Eisei Center Co., Ltd. | Earthquake-proofing reinforcing metal fitting |
IT1316986B1 (it) * | 2000-01-25 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica. |
-
2001
- 2001-09-12 EP EP10183832.4A patent/EP2343077B1/en not_active Expired - Lifetime
- 2001-09-12 ES ES01972468T patent/ES2367778T3/es not_active Expired - Lifetime
- 2001-09-12 HU HU0401693A patent/HU230385B1/hu not_active IP Right Cessation
- 2001-09-12 BR BR0117124-0A patent/BR0117124A/pt active Search and Examination
- 2001-09-12 MX MXPA04002217A patent/MXPA04002217A/es active IP Right Grant
- 2001-09-12 DK DK01972468.1T patent/DK1427427T3/da active
- 2001-09-12 ES ES10183832T patent/ES2431362T3/es not_active Expired - Lifetime
- 2001-09-12 PT PT101838324T patent/PT2343077E/pt unknown
- 2001-09-12 CA CA2457719A patent/CA2457719C/en not_active Expired - Fee Related
- 2001-09-12 PT PT01972468T patent/PT1427427E/pt unknown
- 2001-09-12 JP JP2003526419A patent/JP2005506326A/ja active Pending
- 2001-09-12 SK SK160-2004A patent/SK288335B6/sk not_active IP Right Cessation
- 2001-09-12 WO PCT/IT2001/000472 patent/WO2003022291A1/en active Application Filing
- 2001-09-12 AU AU2001292231A patent/AU2001292231B2/en not_active Ceased
- 2001-09-12 EP EP01972468A patent/EP1427427B1/en not_active Expired - Lifetime
- 2001-09-12 US US10/489,359 patent/US20050137167A1/en not_active Abandoned
- 2001-09-12 AT AT01972468T patent/ATE511846T1/de active
- 2001-09-12 KR KR1020047003203A patent/KR100855331B1/ko active IP Right Grant
- 2001-09-12 CN CN018236324A patent/CN1547477B/zh not_active Expired - Fee Related
- 2001-09-12 SI SI200130998T patent/SI1427427T1/sl unknown
- 2001-09-12 CZ CZ2004-255A patent/CZ307433B6/cs not_active IP Right Cessation
-
2005
- 2005-03-11 HK HK05102146.4A patent/HK1069537A1/xx not_active IP Right Cessation
-
2011
- 2011-08-29 CY CY20111100823T patent/CY1112551T1/el unknown
-
2013
- 2013-08-09 CY CY20131100685T patent/CY1114544T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CN1547477B (zh) | 2010-12-22 |
SI1427427T1 (sl) | 2011-10-28 |
SK288335B6 (sk) | 2016-02-02 |
US20050137167A1 (en) | 2005-06-23 |
CY1114544T1 (el) | 2016-10-05 |
ES2367778T3 (es) | 2011-11-08 |
CA2457719A1 (en) | 2003-03-20 |
EP1427427A1 (en) | 2004-06-16 |
AU2001292231B2 (en) | 2008-06-05 |
CZ307433B6 (cs) | 2018-08-22 |
JP2005506326A (ja) | 2005-03-03 |
PT2343077E (pt) | 2013-08-29 |
HUP0401693A2 (hu) | 2004-12-28 |
EP2343077A1 (en) | 2011-07-13 |
BR0117124A (pt) | 2004-09-28 |
CZ2004255A3 (cs) | 2004-11-10 |
HU230385B1 (hu) | 2016-03-29 |
CA2457719C (en) | 2012-01-03 |
DK1427427T3 (da) | 2011-09-19 |
EP2343077B1 (en) | 2013-07-17 |
SK1602004A3 (en) | 2004-08-03 |
PT1427427E (pt) | 2011-09-13 |
MXPA04002217A (es) | 2004-07-08 |
KR100855331B1 (ko) | 2008-09-04 |
ATE511846T1 (de) | 2011-06-15 |
HK1069537A1 (en) | 2005-05-27 |
WO2003022291A1 (en) | 2003-03-20 |
CN1547477A (zh) | 2004-11-17 |
CY1112551T1 (el) | 2016-02-10 |
EP1427427B1 (en) | 2011-06-08 |
HUP0401693A3 (en) | 2009-06-29 |
ES2431362T3 (es) | 2013-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100855331B1 (ko) | 혈관형성 억제 활성을 가지며 응고억제 효과는 없는,헤파라나제 억제제로서 부분적으로 탈황산화된글리코스아미노글리칸의 유도체 | |
US7781416B2 (en) | Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect | |
AU2001292231A1 (en) | Derivatives of partially desulphated glycogaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect | |
KR100591960B1 (ko) | 황산화된올리고사카라이드의제조및그용도 | |
US5013724A (en) | Process for the sulfation of glycosaminoglycans, the sulfated glycosaminoglycans and their biological applications | |
US5795875A (en) | Therapeutic methods of using O-desulfated heparin derivatives | |
JP6132302B2 (ja) | 抗血管新生活性を有し、抗凝血効果を有さない、ヘパラナーゼ阻害剤としての部分的に脱硫酸化されたグリコサミノグリカンの誘導体 | |
EP2025687A1 (en) | Process for the preparation of heparanase-inhibiting sulfated hyaluronates and products obtained thereby | |
JP2010518251A (ja) | ビオチンまたはビオチン誘導体との少なくとも1つの共有結合を含むヘパリン、これらの調製方法およびこれらの使用 | |
US20080139503A1 (en) | Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect | |
AU2008202261B2 (en) | Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect | |
JP2016014148A (ja) | 抗血管新生活性を有し、抗凝血効果を有さない、ヘパラナーゼ阻害剤としての部分的に脱硫酸化されたグリコサミノグリカンの誘導体 | |
PL212357B1 (pl) | Zmodyfikowana heparyna, jej zastosowanie i zawierająca ją kompozycja farmaceutyczna | |
MXPA97008289A (en) | Preparation and use of oligosacaridos sulfata |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
N231 | Notification of change of applicant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120807 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20130809 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140806 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150806 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20160812 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170818 Year of fee payment: 10 |